Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks Idea Forum | Oncology Day
February 06 2020 - 8:00AM
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a
biopharmaceutical company utilizing sophisticated computational
methods to design de novo protein therapeutics, today
announced that Jonathan Drachman, M.D., Chief Executive Officer,
will participate in a fireside chat at the Guggenheim Healthcare
Talks Idea Forum | Oncology Day in New York City on Thursday,
February 13, 2020 at 10 a.m. Eastern.
A live audio webcast of the session will be available from the
investors section of the Neoleukin website at
http://investor.neoleukin.com/events. An archived replay will also
be available on the company website for at least 30 days following
the event.
About Neoleukin Therapeutics, Inc.Neoleukin is
a biopharmaceutical company creating next generation
immunotherapies for cancer, inflammation and autoimmunity
using de novo protein design technology. Neoleukin uses
sophisticated computational methods to design proteins that
demonstrate specific pharmaceutical properties that provide
potentially superior therapeutic benefit over native
proteins. Neoleukin’s lead product candidate, NL-201, is a
combined IL-2 and IL-15 agonist designed to eliminate alpha
receptor binding. For more information, please visit the Neoleukin
website: www.neoleukin.com.
Safe Harbor / Forward-Looking StatementsThis
press release contains "forward-looking" statements within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties, including market
conditions, that could cause actual results to differ materially
from what Neoleukin expects. Further information on potential risk
factors that could affect Neoleukin’s business and its financial
results are detailed in its most recent Quarterly Report on Form
10-Q for the quarter ended September 30, 2019 filed with
the Securities and Exchange Commission (SEC), and other
reports as filed with the SEC. Neoleukin undertakes no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Contacts:
MediaJulie
Rathbun206-769-9219jrathbun@neoleukin.com
InvestorsSolebury TroutBrian
Korb646-378-2923bkorb@troutgroup.com
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Sep 2023 to Sep 2024